argenx: The Sjögren's Selloff Looks Overdone

Argenx is a biotechnology company that specializes in developing treatments for autoimmune diseases. The company's stock price has been volatile recently due to concerns about its Sjögren's syndrome drug candidate.

Some analysts have raised doubts about the drug's efficacy and safety, and the company's stock price has fallen as a result. However, other analysts remain optimistic about the company's long-term prospects.

Argenx has a strong pipeline of other drug candidates, and it has a partnership with Eli Lilly and Company to develop and commercialize its drugs.